Search for: [Abstract = "gnificant correspondence between the type of tumour regression \(model I\), presence of relapse, mushroom tumour shape, and the risk of secondary loss of the eye. \; In 72 patients \(47.7%\) treated with Ru\-106 isotope and in 152 patients \(89.4%\) treated with I\-125 isotope the visual acuity after the treatment was less than 0.1. In patients with a good visual acuity before the treatment \(0.5\-1\-0\) the acuity deteriorated in 37 individuals \(59.7%\) treated with Ru\-106 and in 43 individuals \(95.6%\) treated with I\-125 isotope. In the same group of patients the visual acuity did not change after the treatment in 25 subjects \(40.3%\) who underwent Ru\-106 brachytherapy and in 2 subjects \(4.4%\) who underwent I\-125 brachytherapy. The analysis of the factors affecting the occurrence of the post\-treatment visual acuity of less than 0.1 revealed a negative influence of the type of applicator \(I\-125\), the height of the tumour \( 8 mm\), the size of the tumour according to the Collaborative Ocular Melanoma Study classification \(large tumours\), the radiation doseapplied to the tumour top \( 100 Gy\) and the presence of symptoms at the time of diagnosis.Ru\-106 and I\-125 brachytherapy is the method which allows effective local control of the disease \(Ru\-106 \-76% vs I\-125 \- 95.1%\) and does not worsen distant prognosis in reference to the occurrence of metastases \(Ru\-106 \-14.6% vs I\-125 \- 15.1%\). In compa"]

Number of results: 1